文献速递免疫规划妇幼与学校卫生

六价疫苗基础与幼儿加强后抗体持久性及学龄期加强免疫原性

Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP∼T vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with Tdap during pregnancy.
PubMed 文献 · Vaccine · 2026-07-10

在既往报告六价DTaP-IPV-HB-PRP∼T疫苗基础与幼儿加强接种后强免疫应答的队列中,本随访研究评估了3岁和5岁抗体持久性及5-7岁含aP疫苗加强的免疫原性。抗体水平3至5岁间下降,破伤风、白喉、脊灰等血清保护率仍高,但抗-HB较低且下降;加强后所有抗原抗体显著升高,足月与早产儿血清保护率均达100%(白喉、破伤风、脊灰1型)或≥96%(脊灰2、3型),百日咳血清转化与疫苗应答率≥93%。

要点

  • 3至5岁抗体水平下降,足月儿一般高于早产儿,抗-HB低于其他抗原且随时间下降。
  • 学龄期含aP加强后所有评估抗原抗体显著升高,百日咳血清转化与疫苗应答率≥93%。
  • 加强后1个月白喉、破伤风、脊灰1型血清保护率均达100%,脊灰2、3型≥96%。

核心结论

  • 数据支持比利时现行孕期Tdap接种策略及儿童加强免疫政策。

研究设计与样本

  • 同一队列随访研究(NCT02511327),基线232名婴儿,3岁纳入128名(足月71、早产57),5岁106名(足月62、早产44),94名(足月57、早产37)在5-7岁经比利时医疗系统接受含aP疫苗加强(Tetravac® N=78,Infanrix-IPV® N=14,Boostrix® N=2),加强数据跨疫苗合并分析。

主要发现

  • 3至5岁两组抗体水平均下降,足月儿一般更高。
  • 3岁和5岁血清保护率保持高且可比,但抗-HB低于其他抗原并随时间下降。
  • 加强后所有评估抗原抗体水平显著升高。
  • 加强后1个月,足月与早产组白喉、破伤风、脊灰1型血清保护率均达100%,脊灰2、3型≥96%,百日咳血清转化与疫苗应答率≥93%。

临床怎么用

  • 支持孕期Tdap接种后按现行程序为足月与早产儿提供儿童期含aP加强免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previously, we reported strong immune responses in term and preterm infants following primary and toddler booster vaccination with a fully liquid DTaP-IPV-HB-PRP ∼ T hexavalent vaccine, irrespective of maternal Tdap vaccination status (NCT02511327). In this follow-up study in the same cohorts, we assessed antibody persistence after the primary series and toddler booster, and evaluated immunogenicity of a second, primary school-age booster of an aP-containing vaccine. METHODS: Antibody persistence was evaluated at 3 and 5 years of age. Immunogenicity was assessed one month after a second aP-containing booster (Tetravac® [N = 78], Infanrix-IPV® [N = 14], Boostrix® [N = 2]) administered at 5-7 years of age through the Belgian healthcare system. All assays were validated and booster data were pooled across vaccines. RESULTS: Of 232 infants in the baseline study, 128 children (71 term, 57 preterm) were included at 3 years, 106 children (62 term, 44 preterm) at 5 years, and 94 children (57 term, 37 preterm) received the school-age aP-containing booster vaccine. Antibody levels declined between 3 and 5 years of age in both groups and were generally higher in term children. Seroprotection rates remained high and comparable at 3 and 5 years of age, except for anti-HB, which was lower than the other antigens and declined over time. Following the booster, antibody levels increased markedly for all assessed antigens. One month post-booster, seroprotection rates reached 100% in both term and preterm groups for diphtheria, tetanus, and poliovirus type 1, and ≥ 96% for poliovirus types 2 and 3. Pertussis seroconversion and vaccine response rates were ≥ 93% in both groups. CONCLUSIONS: These data support current maternal Tdap vaccination strategies and childhood booster vaccination policies in Belgium.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. De Weerdt L, Boisnard F, Maertens K, et al. Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP∼T vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with Tdap during pregnancy. Vaccine. 2026. PMID: 42430876. doi:10.1016/j.vaccine.2026.128915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。